Evidence map›Paper›PMID 20513851›Full record

SynthesisThe British journal of psychiatry : the journal of mental science2010

Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis.

Nicolas A Crossley, Miguel Constante, Philip McGuire, Paddy Power

Open access · bronzeAbstract readComparative StudyMeta-AnalysisReview
In one paragraph

Synthesis in The British journal of psychiatry : the journal of mental science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 6 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 6 syntheses or guidelines pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Are Patients WithFrontiers in pharmacology · 2019
    Pooled it
  4. Guidelines for the Pharmacotherapy of Schizophrenia in Adults.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2017
    Pooled it
  5. Atypical antipsychotics for psychosis in adolescents.The Cochrane database of systematic reviews · 2013
    Pooled it
  6. Pooled it
  7. Trial
  8. Cariprazine in the treatment of schizophrenia: a proof-of-concept trial.International clinical psychopharmacology · 2016
    Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Trajectories of daily antipsychotic use and weight gain in people hospitalized for the first episode of psychosis.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nicolas A CrossleyDivision of Psychological Medicine, Institute of Psychiatry PO 67, De Crespigny Park, London SE58AF. nicolas.crossley@kcl.ac.uk
Miguel Constante
Philip McGuire
Paddy Power
Hologic (Germany) · DESouth London and Maudsley NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis.

aimsTo examine the evidence base for this recommendation.

methodMeta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches.

resultsFifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = -0.1, 95% CI -0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = -0.4, 95% CI -0.5 to -0.2).

conclusionsThere was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.

Indexed as

Antipsychotic AgentsChoice BehaviorFemaleHumansMalePsychotic DisordersRandomized Controlled Trials as TopicWeight GainAntipsychotic Agents

Identifiers

PMID20513851
PMCPMC2878818
OpenAlexW2161045715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.